One of the most promising cell-based immunotherapy cancer treatments is CAR T-cell therapy (Chimeric Antigen Receptor T-cell Therapy). The treatment involves:

• Removing immune system T-cells from the bloodstream

• Shipping T-cell product to a manufacturing laboratory

• Genetically engineer (reprogram) T-cells to produce special receptors on their surface called chimeric antigen receptors, or CARs. This enables the T-cells to better recognize and kill cancer cells.

• Expand T-cells to make billions of new enhanced T-cells.

• Infuse the CAR T-cell product back into the patient to target and kill malignant cancer cells.

Future FDA-approved (commercial) CAR T-cell disease indications will become available in the future.

Our program’s CAR T-cell clinical research studies are open for leukemia, lymphoma, and myeloma patients.

For additional CAR T-cell information, please review our NSH Immunotherapy Program pamphlet.